Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Novel Combination Holds Potential to Address All Hallmarks of Myelofibrosis

June 10th 2021

In an effort to build on the efficacy demonstrated with ruxolitinib, investigators are evaluating combination therapies—specifically the dual inhibition of the JAK-STAT and BET pathways using pelabresib, a novel BET inhibitor.

Larotrectinib Demonstrates Promising Responses in NTRK-Fusion+ CNS Tumors

June 7th 2021

Larotrectinib has demonstrated efficacious responses and disease control in patients with TRK fusion–positive central nervous system tumors.

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors

June 5th 2021

Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.

Larotrectinib Elicits Robust Responses in TRK Fusion Cancer

June 5th 2021

The highly selective, central nervous system-active TRK inhibitor larotrectinib yielded promising response rates in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

Pralsetinib Elicits Durable Anti-Tumor Effects in RET Fusion+ Solid Tumors

June 5th 2021

Pralsetinib demonstrated robust and durable anti-tumor activity, as well as a tolerable safety profile, in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

Zenocutuzumab Demonstrates Clinical Activity in a Variety of NRG1+ Cancers

June 5th 2021

Zenocutuzumab represents a promising novel targeted therapeutic option for patients with NRG1 fusion–positive cancers.

Sotorasib Impresses With Durable Clinical Benefit in KRAS p.G12C+ NSCLC

June 5th 2021

Sotorasib provided continued durable clinical benefit in patients with pretreated KRAS p.G12C–mutated non–small cell lung cancer.

TNO155 Demonstrates Manageable Safety and Consistent SHP2 Inhibition in Advanced Solid Tumors

June 4th 2021

The investigational SHP2 inhibitor TNO155 demonstrated encouraging safety and tolerability, and consistent evidence of SHP2 inhibition in patients with advanced solid tumors.

ACCC Tool Gives Individualized Guidance for Geriatric Assessment Implementation in Patients With Cancer

June 2nd 2021

Melissa (Kah Poh) Loh, BMedSci, MBBCh, BAO, discusses the challenges of utilizing geriatric assessment in oncology and steps that the ACCC resources can provide to institutions that want to incorporate geriatric assessment into practice.

FDA Approves Companion Diagnostic for Sotorasib in KRAS G12C–Mutated Advanced NSCLC

June 1st 2021

The FDA has approved the Guardant360 CDx assay as a companion diagnostic for tumor mutation profiling to identify patients with locally advanced or metastatic non–small cell lung cancer whose tumors harbor the KRAS G12C mutation and may derive benefit from sotorasib.

FDA Approves Infigratinib for FGFR2+ Cholangiocarcinoma

May 28th 2021

The FDA has approved infigratinib for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Artios Pharma and Novartis Set to Collaborate to Develop Next-Generation DDR Therapies

May 28th 2021

Artios Pharma, a company devoted to developing precision medicine–based treatments based on DNA damage response mechanisms, is entering into a global research collaboration with Novartis to develop next-generation DDR targets that will synergize with Novartis’ radioligand therapies.

Daiichi Sankyo and Guardant Health Team Up for Companion Diagnostic for Trastuzumab Deruxtecan in Advanced NSCLC

May 27th 2021

Daiichi Sankyo Inc. is collaborating with Guardant Health Inc. to develop a companion diagnostic for fam-trastuzumab deruxtecan-nxki, which is being studied to treat patients with advanced metastatic HER2-mutated non‒small cell lung cancer.

Dr. Socinski on the Utility of ctDNA Testing in Lung Cancer

May 26th 2021

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

FDA Approves Companion Diagnostic for Amivantamab in EGFR Exon 20–Positive NSCLC

May 25th 2021

The FDA has granted approval to the Guardant360 CDx liquid biopsy assay as the first companion diagnostic for amivantamab-vmjw to determine which patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations may derive benefit from the agent after progressing on, or after, platinum-based chemotherapy.

Larotrectinib Achieves High Marks in NTRK-Mutant Thyroid Cancer

May 24th 2021

Larotrectinib (Vitrakvi) has proved to be highly active in patients with thyroid cancer with NTRK gene fusions, exhibiting rapid and durable disease control.

Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

May 19th 2021

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Selective Kinase Inhibitors Push the Envelope in RET or NTRK Fusion–Positive NSCLC

May 17th 2021

Jose Pacheco, MD, discusses key agents that have significantly improved the care of patients with NSCLC harboring RET or NTRK fusions and efforts being made to address resistance challenges.

Dr. Ross on the Utility of First- and Second-Generation EGFR Inhibitors in EGFR-Mutant NSCLC

May 13th 2021

Helen J. Ross, MD, discusses the utility of first- and second-generation EGFR inhibitors in EGFR-mutant non–small cell lung cancer.